ESMO 2018 Congress

Oncology Meeting Resources

19 Oct - 23 Oct 2018, Munich, Germany

ESMO 2018

Securing access to optimal cancer care!

Presentations (slides) and webcasts are available to ESMO members according to the presenters' agreement to release them. Abstracts are open access. Congress attendees should access via the ESMO Conferences platform .
The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.
Meeting programmeFuture ESMO meetings

> ESMO Videos:  Highlights series   |  Expert Report series

Special Sessions and Tracks

More Resources





Format available

https://oncologypro.esmo.org/Meeting-Resour...LC-aNSCLC-in-the-global-phase-III-ALEX-study

BackgroundThe ALEX study (NCT02075840) showed superior investigator (INV)-assessed PFS with ALC vs crizotinib (CZ) (stratified HR 0.47, 95% CI 0.34–0.65, p 

Date: 19 Oct 2018
Presenter: Rafal Dziadziuszko
Resources: Abstract
Topic: Personalised/Precision Medicine

https://oncologypro.esmo.org/Meeting-Resour...ancer-NSCLC-and-ROS1-kinase-domain-mutations

BackgroundLorlatinib is a potent, brain-penetrant, 3rd-generation ALK/ROS1 TKI active against most known resistance mutations (mut). In a Ph I/II study, lorlatinib showed robust clinical activity in...

Date: 19 Oct 2018
Presenter: Benjamin Solomon
Resources: Abstract
Topic: Personalised/Precision Medicine

https://oncologypro.esmo.org/Meeting-Resour...0-mg-fasted-in-ALK-metastatic-NSCLC-ASCEND-8

BackgroundPrevious PK analysis results from ASCEND-8 study (NCT02299505) showed that ceritinib 450 mg with food had comparable exposure and more favorable GI safety profile than ceritinib 750 mg fasted in patients (pts) with ALK+ NSCLC.

Date: 19 Oct 2018
Presenter: Byoung Chul Cho
Resources: Abstract
Topic: Personalised/Precision Medicine

https://oncologypro.esmo.org/Meeting-Resour...s-and-response-to-tyrosine-kinase-inhibitors

BackgroundThe detection of pro-oncogenic mutations such as mutations in the epidermal growth factor receptor (EGFR) allowed the development of targeted therapies as inhibitor of tyrosine kinase (ITK)(1-3).

Date: 19 Oct 2018
Presenter: Aurélien Brindel
Resources: Abstract
Topic: Personalised/Precision Medicine

https://oncologypro.esmo.org/Meeting-Resour...Lung-Cancer-NSCLC-with-EGFR-Mutations-NEJ009

BackgroundAlthough EGFR-TKI alone has been a standard first-line treatment for pts with advanced NSCLC with EGFR mutations, our phase II study (NEJ005) showed promising efficacy of GCP.

Date: 19 Oct 2018
Presenter: Masahiro Seike
Resources: Abstract
Topics: Anticancer Agents, Personalised/Precision Medicine

https://oncologypro.esmo.org/Meeting-Resour...cussant-LBA60-1381PD-1382PD-1383PD-and-LBA61

Date: 19 Oct 2018
Presenter: Raffaele Califano
Resources: Presentation, Webcast

https://oncologypro.esmo.org/Meeting-Resour...cal-activity-aspects-of-AYA-cancer-survivors

Date: 19 Oct 2018
Presenter: Alexander Stein
Resources: Presentation, Webcast
Topics: Cancers in Adolescents and Young Adults (AYA), Psychosocial Aspects of Cancer, Survivorship

https://oncologypro.esmo.org/Meeting-Resour...gression-When-is-it-time-to-switch-treatment

Date: 19 Oct 2018
Presenter: Stefan Rauh
Resources: Presentation, Webcast
Topic: Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...y-in-lung-cancer-Focus-on-pulmonary-toxicity

Date: 19 Oct 2018
Presenter: Stefan Rauh
Resources: Presentation, Webcast
Topics: Immunotherapy, Complications/Toxicities of Treatment

https://oncologypro.esmo.org/Meeting-Resour...notherapy-in-lung-cancer-General-Discussion2

Date: 19 Oct 2018
Presenter: Pilar Garrido Lopez
Resources: Presentation, Webcast
Topic: Complications/Toxicities of Treatment